April 11, 2017 Allowing Respondents to Skip Items During Electronic Collection of Patient-Reported Outcome (PRO) Data: Does It Matter?
April 11, 2017 Evaluating the Conceptual Equivalence Between Paper and Three Electronic Data Collection Modes of the EQ-5D-5L Health Status Instrument
FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMR
Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments Arnerić, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accele
Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD) Burton, J., et al.; “Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial
Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomar
Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases Kern, V.D., et al.; “Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobili
The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease Conrado, D.J., et al.; “The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarke
